Barclays upgraded shares of Edwards Lifesciences (NYSE:EW) from an equal weight rating to an overweight rating in a research report sent to investors on Thursday, January 4th, Marketbeat reports. They currently have $135.00 price target on the medical research company’s stock, up from their previous price target of $125.00.

Other equities analysts have also issued research reports about the stock. Morgan Stanley cut their price objective on shares of Edwards Lifesciences from $133.00 to $120.00 and set an overweight rating for the company in a research report on Thursday, October 26th. JPMorgan Chase & Co. lowered shares of Edwards Lifesciences from an overweight rating to a neutral rating in a research report on Tuesday, January 2nd. Canaccord Genuity reissued a buy rating and issued a $155.00 price objective on shares of Edwards Lifesciences in a research report on Sunday, October 8th. BMO Capital Markets reissued a buy rating and issued a $137.00 price objective on shares of Edwards Lifesciences in a research report on Friday, December 8th. Finally, SunTrust Banks set a $124.00 price objective on shares of Edwards Lifesciences and gave the company a buy rating in a research report on Wednesday, October 25th. Six analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $129.57.

Shares of Edwards Lifesciences (NYSE:EW) traded down $0.04 on Thursday, reaching $126.86. 206,873 shares of the company’s stock were exchanged, compared to its average volume of 1,095,147. The company has a current ratio of 3.49, a quick ratio of 2.76 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $27,121.21, a PE ratio of 36.85, a P/E/G ratio of 2.05 and a beta of 0.51. Edwards Lifesciences has a one year low of $86.55 and a one year high of $128.61.

Edwards Lifesciences announced that its board has initiated a share repurchase plan on Thursday, December 7th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board believes its shares are undervalued.

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,300 shares of the business’s stock in a transaction that occurred on Friday, December 28th. The shares were sold at an average price of $114.08, for a total transaction of $604,624.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Larry L. Wood sold 6,300 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $121.00, for a total transaction of $762,300.00. Following the sale, the vice president now owns 116,148 shares of the company’s stock, valued at $14,053,908. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 159,620 shares of company stock valued at $17,904,375. 2.13% of the stock is owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Koch Industries Inc. boosted its stake in shares of Edwards Lifesciences by 28,363.1% in the second quarter. Koch Industries Inc. now owns 1,397,254 shares of the medical research company’s stock valued at $1,386,000 after purchasing an additional 1,392,345 shares during the period. Atlantic Trust Group LLC boosted its stake in shares of Edwards Lifesciences by 734.7% in the third quarter. Atlantic Trust Group LLC now owns 914,989 shares of the medical research company’s stock valued at $100,018,000 after purchasing an additional 805,370 shares during the period. Artisan Partners Limited Partnership boosted its stake in shares of Edwards Lifesciences by 90.6% in the second quarter. Artisan Partners Limited Partnership now owns 1,278,532 shares of the medical research company’s stock valued at $151,174,000 after purchasing an additional 607,784 shares during the period. Janus Henderson Group PLC boosted its stake in shares of Edwards Lifesciences by 1,135.0% in the third quarter. Janus Henderson Group PLC now owns 619,703 shares of the medical research company’s stock valued at $67,739,000 after purchasing an additional 569,525 shares during the period. Finally, Old Mutual Global Investors UK Ltd. boosted its stake in shares of Edwards Lifesciences by 83.0% in the third quarter. Old Mutual Global Investors UK Ltd. now owns 1,100,885 shares of the medical research company’s stock valued at $120,337,000 after purchasing an additional 499,436 shares during the period. Institutional investors own 81.78% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Marea Informative and is owned by of Marea Informative. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.mareainformativa.com/2018/01/30/edwards-lifesciences-ew-upgraded-at-barclays-updated-updated-updated.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.